Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
about
The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysisPharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implicationsDid FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend AnalysisAtypical antipsychotic poisoning in young children: a multicentre analysis of poisons centres data.Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012.Differences in Antipsychotic-Related Adverse Events in Adult, Pediatric, and Geriatric Populations.Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents.Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials.Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques.Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challengesSome side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescentsPrescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database studySafety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studiesA Qualitative Study of Antipsychotic Medication Experiences of YouthEarly-life risperidone administration alters maternal-offspring interactions and juvenile play fightingThe role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychoticsProlactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic reviewEvidence review and clinical guidance for the use of ziprasidone in Canada.Prevalence and Treatment Outcomes of Persistent Negative Mood Among Children with Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior.Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE)Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disordersPsychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement.Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents.Possible mechanisms for the skeletal effects of antipsychotics in children and adolescentsEarly Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System.Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain.Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics.Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry.Antipsychotic drug toxicology in children.Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Atypical antipsychotics for disruptive behaviour disorders in children and youths.Fostering Psychotropic Medication Oversight for Children in Foster Care: A National Examination of States' Monitoring Mechanisms.Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.Neural changes induced by antipsychotic administration in adolescence: A review of studies in laboratory rodents.A Pilot Study for Understanding the Perceptions of Australian General Practitioners Regarding Psychopharmacology for Children With Autism Spectrum Disorders.A prospective study of severe irritability in youths: 2- and 4-year follow-up.Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.
P2860
Q26996493-57605A64-1887-435E-93B0-54BF9C73EB09Q28295134-5273D3D3-C454-4676-AB79-91D53655F21FQ28551085-691C160A-6BB8-4296-8CC5-1E0949940333Q30724294-B05C686E-3925-48E2-BB9E-2DDEDBEE3E65Q30773209-B7C32441-86CA-430D-A7C3-EAF6E7C09776Q33617259-D5F89940-8EB2-4B18-97AA-B1D18EAC54AAQ33835596-752C3DFA-9A0A-4525-9D87-589F21333075Q34322230-5FF402FA-B296-42A6-B3D5-76B51D1C121DQ34327978-92B5B1E1-0322-4666-8859-DF6EFE9104DEQ34413021-E973257E-54D0-465B-8870-12B4C2BA557FQ34580449-9C9D9344-8894-4C73-8454-79A9AC6051A8Q34659629-F3F013A0-9C49-4940-A9F5-E48A3C4EDEC3Q34868848-8DB300A3-7D0D-4690-B852-48BE5260D094Q35062673-D20F995B-61FD-434A-8D49-5C281C8EC5E5Q35170541-01ECD87A-43B5-4D3A-9720-2B5EF6D3508AQ35170686-3B07687E-93DC-40AD-BF3E-71CC73C8EA6CQ35208541-DBFCC55B-5237-4485-8D86-BAE756575544Q35641776-99E0F040-1E27-44F7-B6F6-C2481ECA8979Q36186039-ECBD09E3-26F2-4B9A-BB67-D153410A2D22Q36588607-1D11AE13-4CAB-4878-8006-D2E1C8477873Q36708005-90F131E9-5DCC-4E36-91DF-BEDDB537B401Q36773233-3F0553DB-C22A-4487-914F-C1CFF21C5481Q36873932-FEF5D27D-0D35-4FA6-A54F-6B38189E67A5Q36877283-6592E22A-23EF-41CB-8F61-27D73787F03BQ36997233-AADC282D-FC86-41E2-9E40-665F1DA94EF6Q37247927-CB516FCE-70D0-4628-9D54-56F0E385ACC7Q37465755-D7036306-4CA6-42C1-8ED9-22F0BE099500Q37515292-89FE48E0-A153-4EA1-8B2D-0669EF11E162Q37712697-42BA5D5B-6D91-4716-9B82-80D81773806FQ37724890-02A4B050-3860-45B7-B9CD-6EC415F7FBECQ37807890-4E5F4D40-8F41-496D-9D30-6EF40A779206Q37852719-8ED6CC4A-3395-4C21-BA4D-1B8645EE8CB1Q38099224-FFE71409-8CA1-4200-970B-3C2C7AECC9FFQ38632745-7314CC67-DAF8-4538-AD20-5EBCEAF0C350Q38727636-82C90E13-D8CB-4C9C-9868-CCF92FE8C550Q38821689-D5600187-B2CB-4664-943B-6A9B5B8992B4Q38842111-90DE980F-CF8A-4725-9A10-8A7CDFDA9DE5Q38877688-E92A2F90-7907-4BA2-9CEB-D61A95D7C0B6Q39076728-A10B8C4C-B5AE-43B0-A04D-E775AF6FA0F1Q39162868-7BFEE0A9-946E-4F4A-869B-7243FD96A45F
P2860
Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antipsychotics in children and ...... efficacy and safety concerns.
@en
Antipsychotics in children and ...... efficacy and safety concerns.
@nl
type
label
Antipsychotics in children and ...... efficacy and safety concerns.
@en
Antipsychotics in children and ...... efficacy and safety concerns.
@nl
prefLabel
Antipsychotics in children and ...... efficacy and safety concerns.
@en
Antipsychotics in children and ...... efficacy and safety concerns.
@nl
P2093
P1476
Antipsychotics in children and ...... efficacy and safety concerns.
@en
P2093
Alessandro Zuddas
Barbara van Zwieten-Boot
Benedetto Vitiello
Christoph Correll
Mara Parellada
P304
P356
10.1016/J.EURONEURO.2009.04.008
P407
P50
P577
2009-05-24T00:00:00Z